Choose your preferred way to stay informed of new case launches and settlement deadlines
On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio. Management also announced it was initiating cost reductions, including cutting approximately one-third of its workforce. Following this news, ARVN’s stock price fell by $2.39 per share, or approximately 25% to close at $7.23 per share.
In order to be eligible to join the ARVN class action lawsuit, you must have incurred a loss on shares of Arvinas purchased during the class period listed above.
TOP
